Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 3 Date: 23 Mar 2021
Reviewer's report:
Nice work.
Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 3 Date: 23 Mar 2021
Reviewer's report:
Nice work.
Please review this paper.
user
Title: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in
patients with metastatic colorectal cancer
Version: 3 Date: 23 Mar 2021
Reviewer's report:
Nice work.
assistant